Amgen (AMGN)
Develops and manufactures medicines and biosimilars across general medicine, rare disease, inflammation, and oncology.
Something off on this page? Send us feedback.
Discovers, develops, manufactures, and sells medicines and biosimilars across general medicine, rare disease, inflammation, and oncology. A single human-therapeutics segment earns primarily from product sales, with the United States as its largest market and an internal biologics-manufacturing network supporting global supply.
Discovers, develops, manufactures, and sells medicines across general medicine, rare disease, inflammation, oncology, and biosimilars. Core franchises include Prolia and EVENITY in bone health, Repatha in cardiovascular disease, Otezla and TEZSPIRE in inflammation, TEPEZZA, KRYSTEXXA, and UPLIZNA in rare disease, and BLINCYTO and IMDELLTRA in oncology. Most products are biologics, supported by specialized cell-based manufacturing and a commercial presence spanning the United States, Europe, Asia, Latin America, and the Middle East.
Operates as a single human-therapeutics segment, earning primarily from product sales. The United States is its largest market. Performance depends on regulatory approvals, payer coverage and pricing, patent protection, and reliable manufacturing; biosimilar competition is eroding Prolia and XGEVA, while a small group of large wholesalers handles most worldwide gross revenue.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 17, 2026 | UBS | Reiterate | Rating: —Target: $420 | Target: $430 |
| Sep 10, 2026 | HSBC | Downgrade | ||
| Sep 9, 2026 | HSBC | Downgrade | ||
| Sep 8, 2026 | BMO Capital | Downgrade | ||
| Sep 4, 2026 | Wells Fargo | Reiterate | Rating: —Target: $375 | Target: $435 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $13.99B · Total debt $57.30B · Total assets $95.64B · Shareholders' equity $11.69B
- Revenue
- $10.05B
- Operating income
- $3.51B
- Net income
- $2.38B
HistoryDividendAnnual yield
| Institutions | 85.45% | 461.98M shares | |
|---|---|---|---|
| 3,247 holders · as of Jun 30, 2026 | |||
| Insiders | 0.20% | 1.07M shares | |
| 23 holders · as of Sep 4, 2026 | |||
| Other | 14.35% | 77.59M shares | |
| remainder | |||
540.63M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 9.13% | 49.36M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 6.52% | 35.25M | as of Jun 30, 2026 |
State Street CorpInstitution | 5.65% | 30.56M | as of Jun 30, 2026 |
Capital World InvestorsInstitution | 5.38% | 29.08M | as of Jun 30, 2026 |
Invesco Ltd.Institution | 3.02% | 16.32M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 13, 2026 | Rachna Khosla | officer: SVP, Business Development | −1,252 | $416.43 |
| Aug 11, 2026 | Rachna Khosla | officer: SVP, Business Development | −2,000 | $412.57 |
| Aug 6, 2026 | Nancy A. Grygiel | officer: SVP & CCO | −1,000 | $402.16 |
| Aug 6, 2026 | Derek Miller | officer: SVP, Human Resources | −1,821 | $402.54 |
| May 4, 2026 | Nancy A. Grygiel | officer: SVP & CCO | −1,237 | $323.73 |
- AbbVie
Dominant in inflammation with Skyrizi/Rinvoq displacing the TNF class.
- Eli Lilly
Head-to-head in obesity pipeline and dermatology/colorectal oncology.
- Novo Nordisk (ADR)
Dominant GLP-1 incumbent that MariTide must displace in the obesity market.
- Johnson & Johnson
DARZALEX dominates multiple myeloma, contesting Kyprolis regimen slots.
- Regeneron
Direct PCSK9 rival via PRALUENT; Dupixent contests asthma and atopy.
- Merck
KEYTRUDA's checkpoint dominance competes for oncology regimen allocation.
- Novartis (ADR)
Named rival in PCSK9 (siRNA), psoriasis (IL-17), and ITP across three products.
- Bristol-Myers Squibb
IMiD / myeloma franchise contests Kyprolis; SOTYKTU targets Otezla.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Amgen | $402.89 | +2.47% | $212.19B | 24.4 | 17.2 | 5.6 | +9.7% |
| AbbVie | $263.68 | −0.30% | $467.37B | 74.5 | 17.4 | 7.3 | +10.2% |
| Eli Lilly | $1,147.81 | −1.47% | $1.10T | 39.1 | 28.1 | 13.8 | +47.7% |
| Novo Nordisk (ADR) | $39.35 | −1.13% | $176.83B | 9.9 | 16.1 | 3.5 | +1.3% |
| Johnson & Johnson | $265.59 | −1.44% | $649.40B | 31.2 | 22.4 | 6.6 | +6.6% |
| Regeneron | $797.52 | −0.08% | $82.23B | 19.7 | 13.2 | 5.3 | +16.7% |
| Merck | $149.18 | −0.21% | $369.24B | 119.6 | 17.3 | 5.6 | +5.1% |
| Novartis (ADR) | $141.10 | +0.09% | $267.96B | 21.3 | 15.0 | 4.8 | +0.9% |
| Bristol-Myers Squibb | $62.54 | −0.14% | $127.91B | 13.8 | 9.8 | 2.6 | +5.7% |
| Median | 26.2 | 16.7 | 5.4 | +6.2% |